Head to Head Comparison: BioCryst Pharmaceuticals (BCRX) & Its Competitors
BioCryst Pharmaceuticals (NASDAQ: BCRX) is one of 286 public companies in the “Bio Therapeutic Drugs” industry, but how does it compare to its competitors? We will compare BioCryst Pharmaceuticals to similar businesses based on the strength of its valuation, risk, analyst recommendations, dividends, profitability, earnings and institutional ownership.
Risk and Volatility
BioCryst Pharmaceuticals has a beta of 3.07, suggesting that its stock price is 207% more volatile than the S&P 500. Comparatively, BioCryst Pharmaceuticals’ competitors have a beta of 7.84, suggesting that their average stock price is 684% more volatile than the S&P 500.
84.7% of BioCryst Pharmaceuticals shares are owned by institutional investors. Comparatively, 50.3% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 5.6% of BioCryst Pharmaceuticals shares are owned by company insiders. Comparatively, 16.6% of shares of all “Bio Therapeutic Drugs” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
This is a breakdown of current ratings and price targets for BioCryst Pharmaceuticals and its competitors, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|BioCryst Pharmaceuticals Competitors||873||3234||11721||233||2.70|
BioCryst Pharmaceuticals presently has a consensus price target of $9.14, indicating a potential upside of 82.49%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 46.12%. Given BioCryst Pharmaceuticals’ higher probable upside, research analysts clearly believe BioCryst Pharmaceuticals is more favorable than its competitors.
Valuation and Earnings
This table compares BioCryst Pharmaceuticals and its competitors revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|BioCryst Pharmaceuticals||$26.35 million||-$55.14 million||-7.83|
|BioCryst Pharmaceuticals Competitors||$284.49 million||$34.10 million||80.31|
BioCryst Pharmaceuticals’ competitors have higher revenue and earnings than BioCryst Pharmaceuticals. BioCryst Pharmaceuticals is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
This table compares BioCryst Pharmaceuticals and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|BioCryst Pharmaceuticals Competitors||-5,310.77%||-218.27%||-39.48%|
BioCryst Pharmaceuticals competitors beat BioCryst Pharmaceuticals on 7 of the 12 factors compared.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals, Inc. is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. It uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology. The Company’s drug candidates include RAPIVAB, RAPIACTA, ALPIVAB, PERAMIFLU, Avoralstat, BCX7353, other second generation hereditary angioedema (HAE) compounds, Galidesivir and Forodesine. Its product RAPIVAB contains peramivir. ALPIVAB is an intravenous neuraminidase inhibitor. Galidesivir is a broad-spectrum antiviral (BSAV) research program developed for the treatment of hemorrhagic fever viruses. Forodesine is a Purine Nucleoside Phosphorylase (PNP) inhibitor in development by Mundipharma as a treatment for cancer.
Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.